贝伐单抗、紫杉醇、卡帕三者联合治疗复发性卵巢癌的疗效分析

目的 探究贝伐单抗、紫杉醇、卡帕3者联合用药在复发性卵巢癌治疗中的治疗效果.方法 选取复发性上皮性卵巢癌50例,随机分为对照组和观察组,对照组患者给予紫杉醇+卡铂联合用药,观察组患者给予贝伐单抗+紫杉醇+卡铂联合用药,两组疗程均为3周.观察两组患者的临床疗效、不良反应发生情况、生活质量的改善情况,同时对比2组患者的1年生存率和中位生存期.结果 观察组患者的有效率为80%,显著高于对照组(44.00%)(P＜0.05).观察组发生白细胞减少,过敏反应和胃肠道反应的例数显著少于对照组患者(P＜0.05).治疗前2组患者的QOL评分比较无显著性差异(P＞0.05);治疗后观察组的QOL评分显著升高,并显著高于对照组(P＞0.05).观察组患者的中位生存期为21.3个月,显著高于对照组患者的中位生存期(12.3个月)(P＜0.05).结论 贝伐单抗、紫杉醇、卡帕3者联合用药在复发性卵巢癌治疗中的临床效果显著,值得推广使用.

Analysis of Curative Effect of Combination Therapy of Bevacizumab,Paclitaxel andKappa in the Treatment of Recurrent Ovarian Cancer

Objective To explore the efficacy of combination therapy of bevacizumab,paclitaxel and kappa in the treatment for recurrent ovarian cancer.Methods 50 cases of recurrent epithelial ovarian cancer were randomly divided into the control group and the observation group.The control group were treated with paclitaxel and carboplatin combination.The observation group was treated with the combination of bevacizumab,paclitaxel and kappa,the course of treatment in the 2 groups for 3 weeks.Observed the clinical curative effect,adverse reactions,and quality of life of the 2 groups,and compared the 1-year survival rate and median survival time of the 2 groups.Results The effective rate of the observation group was 80%,which was significantly higher than that of the control group(P＜0.05).The number of patients with leukopenia,hypersensitivity and gastrointestinal reactions was significantly lower in the observation group than the control group(P＜0.05).Before treatment,the QOL scores of the 2 groups had no significant difference(P＞0.05).After treatment,the QOL score of the observation group was significantly higher than that of the control group(P＞0.05).The median survival time was 21.3 months in the observation group,which was significantly higher than that of the control group(12.3 moths)(P＜0.05).Conclusion The combination of bevacizumab,paclitaxel and kappa in the treatment of recurrent ovarian cancer has significant clinical effect and is worthy of promotion.